Search research articles
Contact Us
Filters
Showing results (181-190 of 200) with videos related to
Page
of 20
Sort By:
The Journal of Infectious Diseases
|
August 11, 1992
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network
B S Graham, R B Belshe, M L Clements, et al.
The Journal of Infectious Diseases
|
May 1, 1995
A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children
R A Karron, P F Wright, S L Hall, et al.
Journal of Clinical Microbiology
|
August 1, 1986
Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection
D K Wagner, B S Graham, P F Wright, et al.
The Journal of Infectious Diseases
|
November 1, 1989
Evaluation of a new highly purified pertussis vaccine in infants and children
K M Edwards, R B Bradley, M D Decker, et al.
The Journal of Infectious Diseases
|
December 1, 1995
A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children
R A Karron, P F Wright, F K Newman, et al.
The Journal of Infectious Diseases
|
July 1, 1988
Changing presentation of herpes simplex virus infection in neonates
R J Whitley, L Corey, A Arvin, et al.
Reviews of Infectious Diseases
|
July 1, 1983
Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children--a multicentered evaluation of dosage and safety
P F Wright, J D Cherry, H M Foy, et al.
Clinical and Experimental Immunology
|
November 1, 1994
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network
G J Gorse, D H Schwartz, B S Graham, et al.
The Journal of Infectious Diseases
|
October 1, 1994
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network
B S Graham, G J Gorse, D H Schwartz, et al.
The Journal of Infectious Diseases
|
March 1, 1993
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network
B S Graham, T J Matthews, R B Belshe, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 200) with videos related to
Sort By:
Page
of 20
The Journal of Infectious Diseases
|
August 11, 1992
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network
B S Graham, R B Belshe, M L Clements, et al.
The Journal of Infectious Diseases
|
May 1, 1995
A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children
R A Karron, P F Wright, S L Hall, et al.
Journal of Clinical Microbiology
|
August 1, 1986
Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection
D K Wagner, B S Graham, P F Wright, et al.
The Journal of Infectious Diseases
|
November 1, 1989
Evaluation of a new highly purified pertussis vaccine in infants and children
K M Edwards, R B Bradley, M D Decker, et al.
The Journal of Infectious Diseases
|
December 1, 1995
A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children
R A Karron, P F Wright, F K Newman, et al.
The Journal of Infectious Diseases
|
July 1, 1988
Changing presentation of herpes simplex virus infection in neonates
R J Whitley, L Corey, A Arvin, et al.
Reviews of Infectious Diseases
|
July 1, 1983
Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children--a multicentered evaluation of dosage and safety
P F Wright, J D Cherry, H M Foy, et al.
Clinical and Experimental Immunology
|
November 1, 1994
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network
G J Gorse, D H Schwartz, B S Graham, et al.
The Journal of Infectious Diseases
|
October 1, 1994
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network
B S Graham, G J Gorse, D H Schwartz, et al.
The Journal of Infectious Diseases
|
March 1, 1993
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network
B S Graham, T J Matthews, R B Belshe, et al.
Page
of 20